IP Group CEO on 2025 highlights, NAV uplift, Pfizer royalties & capital allocation

Core Insights - IP Group PLC's CEO Greg Smith highlighted a 13% growth in NAV per share for 2025 and discussed strategic developments within the company's portfolio [1] - The company's licensing of intellectual property related to an anti-obesity program to Pfizer, following Pfizer's acquisition of Metsera, is expected to generate significant long-term royalty income, with an asset valuation of £130 million, approximately 14p per share [2] Portfolio Milestones - The successful IPO of Hinge Health on the New York Stock Exchange resulted in approximately 50 times returns on the original investment for IP Group after exiting its position [3] - The sale of Monolith to Nasdaq-listed CoreWeave is another significant development, providing additional proceeds with further payments anticipated in 2026 [3] Funding Activities - Artios Pharma secured $100 million in Series D financing, while Oxa raised £100 million, supported by investors such as the National Wealth Fund and Nvidia's venture arm [4] - IP Group has been returning capital to shareholders through share buybacks and aims for £250 million in exits by the end of 2027 [4]